TY - JOUR
T1 - Molecular cytogenetics of ovarian granulosa cell tumors by comparative genomic hybridization
AU - Lin, Yue Shan
AU - Eng, Hock Liew
AU - Jan, Yee Jee
AU - Lee, Herng Sheng
AU - Ho, William L.
AU - Liou, Chiou Ping
AU - Lee, Wen Yu
AU - Tzeng, Ching Cherng
N1 - Funding Information:
This study was supported by a grant (9317) from Chi Mei Medical Center, Tainan, Taiwan.
PY - 2005/4
Y1 - 2005/4
N2 - Objective. Patients with stage I granulosa cell tumors (GCTs) may occasionally develop metastasis, which is hard to predict using pathologic criteria. It is interesting to elucidate whether certain chromosomal imbalances (CIs), detected by comparative genomic hybridization (CGH), could be useful prognostic markers. Methods. CGH was used to identify CI(s) in 37 adult-type GCTs from 36 women. Nonrandom CIs were compared with clinical and pathological features to evaluate their significance as a prognostic marker. Results. Twenty-two (61%) of the 36 primary tumors had CIs. One woman's tumor showed identical CIs to another tumor that occurred in contralateral ovary 2 years later, supporting a metastatic nature. The nonrandom CIs included losses of 22q (31%), 1p33-p36 (6%), 16p13.1 (6%), and 16q (6%) and gains of 14 (25%), 12 (14%), and 7p15-p21 (6%). No tumor exhibited high-level amplification. The associations between each CI and pathological features, including the growth pattern, tumor size, and mitotic activity, were not evident. The only CI repeatedly detected in tumors with metastasis was monosomy 22, which presented in 2 of the 4 cases with metastasis but also in 2 of the 5 cases without recurrence for more than 5 years. Conclusions. Monosomy 22 was the most common CI in GCTs, which often coexisted with trisomy 14 (in 55% cases). Deletion of 22q seems to be, albeit not very specific, associated with the risk of early metastases of stage I disease. The role of loss-of-function mutation(s) of certain putative tumor suppressor gene(s) on 22q is worthy of further investigations.
AB - Objective. Patients with stage I granulosa cell tumors (GCTs) may occasionally develop metastasis, which is hard to predict using pathologic criteria. It is interesting to elucidate whether certain chromosomal imbalances (CIs), detected by comparative genomic hybridization (CGH), could be useful prognostic markers. Methods. CGH was used to identify CI(s) in 37 adult-type GCTs from 36 women. Nonrandom CIs were compared with clinical and pathological features to evaluate their significance as a prognostic marker. Results. Twenty-two (61%) of the 36 primary tumors had CIs. One woman's tumor showed identical CIs to another tumor that occurred in contralateral ovary 2 years later, supporting a metastatic nature. The nonrandom CIs included losses of 22q (31%), 1p33-p36 (6%), 16p13.1 (6%), and 16q (6%) and gains of 14 (25%), 12 (14%), and 7p15-p21 (6%). No tumor exhibited high-level amplification. The associations between each CI and pathological features, including the growth pattern, tumor size, and mitotic activity, were not evident. The only CI repeatedly detected in tumors with metastasis was monosomy 22, which presented in 2 of the 4 cases with metastasis but also in 2 of the 5 cases without recurrence for more than 5 years. Conclusions. Monosomy 22 was the most common CI in GCTs, which often coexisted with trisomy 14 (in 55% cases). Deletion of 22q seems to be, albeit not very specific, associated with the risk of early metastases of stage I disease. The role of loss-of-function mutation(s) of certain putative tumor suppressor gene(s) on 22q is worthy of further investigations.
KW - CGH
KW - Chromosomal imbalance
KW - Comparative genomic hybridization
KW - Granulosa cell tumor
KW - Ovary
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=15544389043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=15544389043&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2004.12.014
DO - 10.1016/j.ygyno.2004.12.014
M3 - Article
C2 - 15790439
AN - SCOPUS:15544389043
SN - 0090-8258
VL - 97
SP - 68
EP - 73
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 1
ER -